Literature DB >> 15678343

[Salivary duct carcinoma of the submandibular gland].

M Jaehne1, A Dippel, C Sagowski.   

Abstract

BACKGROUND: Salivary duct carcinoma (SDC) is a rare adenocarcinoma of the salivary glands which usually occurs in the parotid gland (approx. 80%), but is also found in the submandibular gland (approx. 12%) and the minor salivary glands. Due to the low incidence of this tumour-particularly in terms of involvement of the submandibular and minor salivary glands-only limited clinical data is available. PATIENTS/
METHOD: In a retrospective investigation, follow-ups of six patients with a SDC of the submandibular gland were analysed and the surgical measures evaluated for their efficiency.
RESULTS: At the time of diagnosis, varying tumor stages were present (2xT1, 3xT2, 1xT1). Initial lymph node metastasis was observed in four (66.6%) of the six patients. In all patients, the submandibular gland was resected and neck dissection performed, in two cases (33,3%) this was followed by radiotherapy. Four patients developed a life-threatening local recurrence. Only one patient developed distant metastasis. Two thirds of the patients died due to tumor-related disease after an average of 35.5 months.
CONCLUSION: The clinical course of patients with SDC of the submandibular gland exhibits a high (66.6%) rate of local recurrence, crucial for the following clinical course. The treatment of these patients, therefore, must include radical tumor resection as well as tissue resection with a wide margin.

Entities:  

Mesh:

Year:  2005        PMID: 15678343     DOI: 10.1007/s00106-004-1204-z

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  17 in total

1.  Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours.

Authors:  N Kamio
Journal:  Virchows Arch       Date:  1996-05       Impact factor: 4.064

2.  Low malignant intraductal carcinoma on the hard palate: a variant of salivary duct carcinoma?

Authors:  Y Tatemoto; A Ohno; T Osaki
Journal:  Eur J Cancer B Oral Oncol       Date:  1996-07

Review 3.  Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases.

Authors:  J E Lewis; B C McKinney; L H Weiland; J A Ferreiro; K D Olsen
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

Review 4.  Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).

Authors:  H A Burris
Journal:  Semin Oncol       Date:  2000-04       Impact factor: 4.929

5.  Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report.

Authors:  Janet C Ruzich; Marlyn C Ciesla; Joseph I Clark
Journal:  Head Neck       Date:  2002-04       Impact factor: 3.147

6.  Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma.

Authors:  A Felix; A K El-Naggar; M F Press; N G Ordonez; I Fonseca; S L Tucker; M A Luna; J G Batsakis
Journal:  Hum Pathol       Date:  1996-06       Impact factor: 3.466

7.  Salivary duct adenocarcinoma: a high grade malignancy.

Authors:  K K Hui; J G Batsakis; M A Luna; B Mackay; R M Byers
Journal:  J Laryngol Otol       Date:  1986-01       Impact factor: 1.469

8.  Salivary duct carcinoma--a highly aggressive salivary gland tumour with overexpression of c-erbB-2.

Authors:  H B Hellquist; M G Karlsson; C Nilsson
Journal:  J Pathol       Date:  1994-01       Impact factor: 7.996

9.  Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein.

Authors:  L Barnes; U Rao; L Contis; J Krause; A Schwartz; P Scalamogna
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1994-07

10.  Salivary duct carcinoma metastasizing to the small bowel.

Authors:  B Kruslin; M Scukanec-Spoljar; V Separović; S Manojlović; D Janković; Z Danilović
Journal:  Tumori       Date:  1996 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.